Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Geneplus-multifocal synchronous lung cancer

ABSTRACT: Genomic heterogeneity of multifocal synchronous lung cancer with diversely pathological subtypes

INSTRUMENT(S): -

ORGANISM(S): Homo Sapiens

SUBMITTER: Beijing Geneplus Institute

PROVIDER: PRJEB44390 | EVA | 2021-04-22

REPOSITORIES: EVA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	189008313TD.vcf.gz	Vcf
	189008313TD.vcf.gz.csi	Vcf
	189008313TD.vcf.gz.tbi	Vcf
	189008314TD.vcf.gz	Vcf
	189008314TD.vcf.gz.csi	Vcf

Items per page:

1 - 5 of 75

Similar Datasets

Genomic imbalances of lung cancer

Project description:The array comparative genomic hybridization (aCGH) was perform to identify regions with genomic imbalance in lung cancer.The aCGH analysis detected a total of 325 regions with genomic imbalance in all 8 lung cancer samples, ranging from focal rearrangements (70 kb–5 Mb) to chromosome-arm alterations with chromosomal segments amplification or deletion. Among these mutations, a total of 115 genomic imbalances were discovered occurring at high frequency varying from 25% to 50%.

2016-11-17 | GSE89927 | GEO

Transcriptomic heterogeneity of EGFR-mutant non-small cell lung cancer evolution towards small cell lung cancer

Project description:Transcriptomic heterogeneity of EGFR-mutant non-small cell lung cancer evolution towards small cell lung cancer

| PRJNA1081397 | ENA

OncoArray: Lung Cancer

Project description:OncoArray: Lung Cancer

| PRJNA368779 | ENA

Proteogenomic characterization analysis of human large cell lung cancer

Project description:Current clinical therapy of non-small cell lung cancer depends on histo-pathological classification. This approach poorly predicts clinical outcome for individual patients. Proteogenomic characterization analysis holds promise to improve clinical stratification, thus paving the way for individualized therapy. We investigated proteogenomic characterization and performed comprehensive integrative genomic analysis of human large cell lung cancer. Here we analyzed proteomes of 29 paired normal lung tissues and large cell lung cancer, identified significantly deregulated proteins associated with large cell lung cancer.

2019-01-16 | PXD012393 |

Transcription profiling by array of mouse small cell lung cancer tumor samples

Project description:Expressionarray data for A functional role for tumor cell heterogeneity in a mouse model of Small Cell Lung Cancer

2011-02-19 | E-NCMF-37 | biostudies-arrayexpress

Intratumoral heterogeneity of small cell lung cancer

Project description:Small cell lung cancer (SCLC) is a highly malignant tumor with extensive genomic alterations as detected by single-region sequencing. Yet, the intratumoral heterogeneity (ITH) of SCLC remains unknown. We subjected 120 tumor samples from 40 stage I-III SCLC to multi-regional whole-exome sequencing.

2021-07-02 | PRJEB45988 | EVA

Progressive genomic instability in the FVB/KrasLA2 mouse model of lung cancer

Project description:Alterations in DNA copy number contribute to the development and progression of cancers and are common in epithelial tumors. We have used array Comparative Genomic Hybridization (aCGH) to visualize DNA copy number alterations across the genomes of lung tumors in the KrasLA2 model of lung cancer. Copy number gain involving the Kras locus, as focal amplification or whole chromosome gain, is the most common alteration in these tumors, and with a prevalence that increased significantly with increasing tumor size. Furthermore, Kras amplification was the only major genomic event among the smallest lung tumors, suggesting that this alteration occurs early during the development of mutant Kras driven lung cancers. Recurring gains and deletions of other chromosomes occur progressively more frequently among larger tumors. These results are in contrast to a previous aCGH analysis of lung tumors from KrasLA2 mice on a mixed genetic background, in which relatively few DNA copy alterations were observed regardless of tumor size. Our model features the KrasLA2 allele on the inbred FVB/N mouse strain, and in this genetic background there is a highly statistically significant increase in level of genomic instability with increasing tumor size. These data suggest that recurring DNA copy alterations are important for tumor progression in the KrasLA2 model of lung cancer, and that the requirement for these alterations may be dependent on the genetic background of the mouse strain. The KrasLA2 allele, originally on a C57BL6/129svJae mixed background, was backcrossed into the FVB/N background for more than 10 generations in order to minimize the effect of genetic heterogeneity on lung tumor development. Mice were sacrificed at 6 months of age.

2011-11-22 | E-GEOD-29230 | biostudies-arrayexpress

lung cancer 5hmc sequencing

Project description:lung cancer 5hmc sequencing

2022-10-10 | OEX00020577 | NODE

RASSF1A controls Tissue Stiffness and Cancer Stem-like Cells in Lung Adenocarcinoma

Project description:Lung cancer remains the leading cause of cancer-related death due to poor treatment responses and resistance arising from tumor heterogeneity. Here we show that adverse prognosis associated with epigenetic silencing of the tumour suppressor RASSF1A is due to increased deposition of extracellular matrix (ECM), tumour stiffness and metastatic dissemination in vitro and in vivo. We find that lung cancer cells with RASSF1A promoter methylation display constitutive nuclear YAP1 and expression of collagen prolylhydroxylase (P4HA2) which increases collagen deposition. Furthermore, we identify that elevated collagen creates a stiff-ECM which in turn triggers cancer stem-like programming and metastatic dissemination in vivo. Re-expression of RASSF1A or inhibition of P4HA2 activity reverse these effects and increase markers of lung differentiation (TTF-1, Mucin5B). Our study identifies RASSF1A as a clinical biomarker associated with mechanical properties of ECM which increases levels of cancer stemness and risk of metastatic progression in lung adenocarcinoma. Moreover, we highlight P4HA2 as a potential target for uncoupling ECM signals that support cancer stemness.

2019-05-20 | PXD012694 | Pride

Lung cancer bone metastasis

Project description:Lung cancer bone metastasis

| PRJNA934341 | ENA